These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26425251)

  • 21. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; Kuo CT; Yeh YH; Chang SH; Wu LS; Lee HF; Tu HT; See LC
    J Am Coll Cardiol; 2016 Sep; 68(13):1389-1401. PubMed ID: 27659460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.
    Augoustides JG
    J Cardiothorac Vasc Anesth; 2011 Dec; 25(6):1208-12. PubMed ID: 21982327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.
    Zhou W; Schwarting S; Illanes S; Liesz A; Middelhoff M; Zorn M; Bendszus M; Heiland S; van Ryn J; Veltkamp R
    Stroke; 2011 Dec; 42(12):3594-9. PubMed ID: 21998060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
    Brem E; Koyfman A; Foran M
    J Emerg Med; 2013 Jul; 45(1):143-9. PubMed ID: 23375217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function.
    Maw TT; Henry BL; Singh T
    Clin Nephrol Case Stud; 2014; 2():18-22. PubMed ID: 29043124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
    Stangier J; Clemens A
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Dabigatran therapy--perioperative management and interpretation of coagulation tests].
    Spannagl M; Bauersachs R; Debus ES; Gawaz M; Gerlach H; Haas S; Hach-Wunderle V; Lindhoff-Last E; Riess H; Schellong S; Schinzel H; Bode C
    Hamostaseologie; 2012; 32(4):294-305. PubMed ID: 23114798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
    Stangier J
    Clin Pharmacokinet; 2008; 47(5):285-95. PubMed ID: 18399711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
    Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
    Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The evolving role of dabigatran etexilate in clinical practice.
    Hellenbart E; Drambarean B; Lee J; Nutescu EA
    Expert Opin Pharmacother; 2015; 16(13):2053-72. PubMed ID: 26245513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.
    Ganetsky M; Babu KM; Salhanick SD; Brown RS; Boyer EW
    J Med Toxicol; 2011 Dec; 7(4):281-7. PubMed ID: 21887485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful hemostasis and reversal of highly elevated PT/INR after dabigatran etexilate use in a patient with acute kidney injury.
    Jones JM; Ryan HM; Tieszen M; Leedahl DD
    Am J Emerg Med; 2016 Apr; 34(4):758.e5-6. PubMed ID: 26324007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dabigatran in clinical practice: Contemporary overview of the evidence.
    Ageno W; Eikelboom J; Lip GY
    Int J Cardiol; 2016 Oct; 220():417-28. PubMed ID: 27390965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
    Gulseth MP; Wittkowsky AK; Fanikos J; Spinler SA; Dager WE; Nutescu EA
    Pharmacotherapy; 2011 Dec; 31(12):1232-49. PubMed ID: 22122184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.
    Dzeshka MS; Lip GY
    Expert Opin Drug Saf; 2015 Jan; 14(1):45-62. PubMed ID: 25341529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dabigatran, intracranial hemorrhage, and the neurosurgeon.
    Awad AJ; Walcott BP; Stapleton CJ; Yanamadala V; Nahed BV; Coumans JV
    Neurosurg Focus; 2013 May; 34(5):E7. PubMed ID: 23634926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.
    Tran A; Cheng-Lai A
    Cardiol Rev; 2011; 19(3):154-61. PubMed ID: 21464643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.